Biotech Coverage

Biotech names covered by Thomas Bouman. Each one opens with a full thesis: what the company develops, what the call rests on, the risks, and what would prove it wrong. After that it stays current through short update notes around FDA decisions, readouts and results, each making a call that is scored later, and developments that simply record what happened. Nothing is rewritten afterwards. Not financial advice.